{"id":22597,"date":"2022-03-28T18:16:17","date_gmt":"2022-03-28T17:16:17","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=22597"},"modified":"2022-03-28T18:16:21","modified_gmt":"2022-03-28T17:16:21","slug":"models-for-financing-antibiotic-development-to-address-antimicrobial-resistance","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/","title":{"rendered":"Models for Financing Antibiotic Development to Address Antimicrobial Resistance"},"content":{"rendered":"\n<p>Article published on the <a href=\"https:\/\/milkeninstitute.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">Milken Institute<\/a> website on March 24, 2022<\/p>\n\n\n\n<p>The\u00a0<a href=\"https:\/\/milkeninstitute.org\/financial-innovations-labs\" target=\"_blank\" rel=\"noreferrer noopener\">Financial Innovations Labs\u00ae<\/a>\u00a0and\u00a0<a href=\"https:\/\/milkeninstitute.org\/centers\/fastercures\" target=\"_blank\" rel=\"noreferrer noopener\">FasterCures<\/a>\u00a0teams have collaborated on a project\u202fto identify new models for financing the antimicrobial resistant antibiotic pipeline. These past 18 months have demonstrated how consequential public health risks are to the economy. As investors broadly increase their focus on ESG investments, antimicrobial resistance (AMR) is likely to be of growing concern. <\/p>\n\n\n\n<p>If AMR continues to remain unchecked, it may cost the global economy as much as $100 trillion by 2050. Recognizing the growing prevalence of drug-resistant infections, leading health organizations have declared AMR one of today&#8217;s most significant global health threats.<\/p>\n\n\n\n<p>The Milken Institute, in partnership with\u00a0<a href=\"https:\/\/wellcome.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">Wellcome Trust<\/a>, hosted a Financial Innovations Lab to examine existing and new\u202fsolutions\u202fthat can\u202frevitalize the pipeline of antibiotics. During the Lab session, participants discussed possible funding and financing mechanisms\u202fto spur the\u202fresearch and development of antibiotics\u202fand reward the successful development of new products.\u202fDiscussions included exploring the option of a social impact bond to pay for antibiotic development similar to traditional infrastructure. <\/p>\n\n\n\n<p>Utilizing the Milken Institute&#8217;s network, participants tested the feasibility of a blended capital vehicle, as well as debt options, understanding return expectations at varying stages of drug development.\u00a0<\/p>\n\n\n\n<p>Download pdf <a href=\"https:\/\/milkeninstitute.org\/sites\/default\/files\/2022-03\/FIL-AMR%20v3.22.22.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on the Milken Institute website on March 24, 2022 The\u00a0Financial Innovations Labs\u00ae\u00a0and\u00a0FasterCures\u00a0teams have collaborated on a project\u202fto identify new models for financing the antimicrobial resistant antibiotic pipeline. These past 18 months have demonstrated how consequential public health risks are to the economy. As investors broadly increase their focus on ESG investments, antimicrobial resistance [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":22599,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Models for Financing Antibiotic Development to Address Antimicrobial Resistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Models for Financing Antibiotic Development to Address Antimicrobial Resistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-28T17:16:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-28T17:16:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"413\" \/>\n\t<meta property=\"og:image:height\" content=\"534\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Models for Financing Antibiotic Development to Address Antimicrobial Resistance\",\"datePublished\":\"2022-03-28T17:16:17+00:00\",\"dateModified\":\"2022-03-28T17:16:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\"},\"wordCount\":215,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\",\"name\":\"Models for Financing Antibiotic Development to Address Antimicrobial Resistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg\",\"datePublished\":\"2022-03-28T17:16:17+00:00\",\"dateModified\":\"2022-03-28T17:16:21+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg\",\"width\":413,\"height\":534},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Reviews, reports and recommendations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Models for Financing Antibiotic Development to Address Antimicrobial Resistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Models for Financing Antibiotic Development to Address Antimicrobial Resistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/","og_locale":"en_GB","og_type":"article","og_title":"Models for Financing Antibiotic Development to Address Antimicrobial Resistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-03-28T17:16:17+00:00","article_modified_time":"2022-03-28T17:16:21+00:00","og_image":[{"width":413,"height":534,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Models for Financing Antibiotic Development to Address Antimicrobial Resistance","datePublished":"2022-03-28T17:16:17+00:00","dateModified":"2022-03-28T17:16:21+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/"},"wordCount":215,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/","name":"Models for Financing Antibiotic Development to Address Antimicrobial Resistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg","datePublished":"2022-03-28T17:16:17+00:00","dateModified":"2022-03-28T17:16:21+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/Fininnovlabs.jpg","width":413,"height":534},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/models-for-financing-antibiotic-development-to-address-antimicrobial-resistance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Reviews, reports and recommendations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/"},{"@type":"ListItem","position":4,"name":"Models for Financing Antibiotic Development to Address Antimicrobial Resistance"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-14 23:31:45","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/22597"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=22597"}],"version-history":[{"count":4,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/22597\/revisions"}],"predecessor-version":[{"id":22609,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/22597\/revisions\/22609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/22599"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=22597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=22597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=22597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}